Europe Animal Parasiticides Market

Europe Animal Parasiticides Market Size (2022 to 2027)

As per the report, the European Animal Parasiticides Market has been calculated at USD 2.76 billion in 2022. It is estimated to be growing at a CAGR of 5.8% and worth USD 3.66 billion by 2027.

The market shows substantial potential during the forecasting period. It continues to expand with a gradual increase in awareness about animal health.

Animal parasiticides are the medicines for animals that destroy all the parasites other than fungi and bacteria present on animals. They are normally non-reactive substances which are mixed with each other and may contain many different ingredients. Most ingredients of parasiticidal nature have the same kind of chemical structures and have some common characteristics. Many a time, they are segmented according to chemical families. Animal parasiticides are considered very important for the protection of animals from parasitic diseases.

Growing expenditure on the healthcare of animals and increasing the adoption of pet animals are the factors responsible for the growth of the Europe Animal Parasiticides market. Also, the growing concern for meat quality as well as other animal products has led to the development of the animal healthcare sector. However, increased acceptance of the vegetarian lifestyle combined with strict restrictions on the approval for animal parasiticides is hindering the growth of the Europe animal parasiticides market.

This research report on the European Animal Parasiticides Market has been segmented and sub-segmented into the following categories:

By Product: 

• Ectoparasiticides
• Endoparasiticides

By Animal type: 

• Food-producing Animals
• Companion Animals

By Country: 

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Companies playing a notable role in the European animal parasiticides market profiled in the report are Sanofi S.A. (Merial), Ceva Sante Animale, Virbac SA, Vetoquinol S.A., Eli Lilly and Company, Zoetis Inc., Merck & Co Inc., Bayer AG, Boehringer Ingelheim GmbH and Perrigo Co. plc.